Radium 223 dichloride for prostate cancer treatment

Prostate cancer is the most common malignant disease in men. Several therapeutic agents have been approved during the last 10 years. Among them, radium-223 dichloride (Xofigo(®)) is a radioactive isotope that induces irreversible DNA double-strand breaks and consequently tumor cell death. Radium-223...

Descripción completa

Detalles Bibliográficos
Autores principales: Deshayes, Emmanuel, Roumiguie, Mathieu, Thibault, Constance, Beuzeboc, Philippe, Cachin, Florent, Hennequin, Christophe, Huglo, Damien, Rozet, François, Kassab-Chahmi, Diana, Rebillard, Xavier, Houédé, Nadine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593411/
https://www.ncbi.nlm.nih.gov/pubmed/28919714
http://dx.doi.org/10.2147/DDDT.S122417
_version_ 1783263029456011264
author Deshayes, Emmanuel
Roumiguie, Mathieu
Thibault, Constance
Beuzeboc, Philippe
Cachin, Florent
Hennequin, Christophe
Huglo, Damien
Rozet, François
Kassab-Chahmi, Diana
Rebillard, Xavier
Houédé, Nadine
author_facet Deshayes, Emmanuel
Roumiguie, Mathieu
Thibault, Constance
Beuzeboc, Philippe
Cachin, Florent
Hennequin, Christophe
Huglo, Damien
Rozet, François
Kassab-Chahmi, Diana
Rebillard, Xavier
Houédé, Nadine
author_sort Deshayes, Emmanuel
collection PubMed
description Prostate cancer is the most common malignant disease in men. Several therapeutic agents have been approved during the last 10 years. Among them, radium-223 dichloride (Xofigo(®)) is a radioactive isotope that induces irreversible DNA double-strand breaks and consequently tumor cell death. Radium-223 dichloride is a calcium-mimetic agent that specifically targets bone lesions. Radium-223 dichloride has been approved for the treatment of metastatic castration-resistant prostate cancer with symptomatic bone metastases, without known visceral metastases. In this review, first we summarize the interplay between prostate tumor cells and bone microenvironment; then, we discuss radium-223 dichloride mechanism of action and present the results of the available clinical trials and future developments for this new drug.
format Online
Article
Text
id pubmed-5593411
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-55934112017-09-15 Radium 223 dichloride for prostate cancer treatment Deshayes, Emmanuel Roumiguie, Mathieu Thibault, Constance Beuzeboc, Philippe Cachin, Florent Hennequin, Christophe Huglo, Damien Rozet, François Kassab-Chahmi, Diana Rebillard, Xavier Houédé, Nadine Drug Des Devel Ther Review Prostate cancer is the most common malignant disease in men. Several therapeutic agents have been approved during the last 10 years. Among them, radium-223 dichloride (Xofigo(®)) is a radioactive isotope that induces irreversible DNA double-strand breaks and consequently tumor cell death. Radium-223 dichloride is a calcium-mimetic agent that specifically targets bone lesions. Radium-223 dichloride has been approved for the treatment of metastatic castration-resistant prostate cancer with symptomatic bone metastases, without known visceral metastases. In this review, first we summarize the interplay between prostate tumor cells and bone microenvironment; then, we discuss radium-223 dichloride mechanism of action and present the results of the available clinical trials and future developments for this new drug. Dove Medical Press 2017-09-06 /pmc/articles/PMC5593411/ /pubmed/28919714 http://dx.doi.org/10.2147/DDDT.S122417 Text en © 2017 Deshayes et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Deshayes, Emmanuel
Roumiguie, Mathieu
Thibault, Constance
Beuzeboc, Philippe
Cachin, Florent
Hennequin, Christophe
Huglo, Damien
Rozet, François
Kassab-Chahmi, Diana
Rebillard, Xavier
Houédé, Nadine
Radium 223 dichloride for prostate cancer treatment
title Radium 223 dichloride for prostate cancer treatment
title_full Radium 223 dichloride for prostate cancer treatment
title_fullStr Radium 223 dichloride for prostate cancer treatment
title_full_unstemmed Radium 223 dichloride for prostate cancer treatment
title_short Radium 223 dichloride for prostate cancer treatment
title_sort radium 223 dichloride for prostate cancer treatment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593411/
https://www.ncbi.nlm.nih.gov/pubmed/28919714
http://dx.doi.org/10.2147/DDDT.S122417
work_keys_str_mv AT deshayesemmanuel radium223dichlorideforprostatecancertreatment
AT roumiguiemathieu radium223dichlorideforprostatecancertreatment
AT thibaultconstance radium223dichlorideforprostatecancertreatment
AT beuzebocphilippe radium223dichlorideforprostatecancertreatment
AT cachinflorent radium223dichlorideforprostatecancertreatment
AT hennequinchristophe radium223dichlorideforprostatecancertreatment
AT huglodamien radium223dichlorideforprostatecancertreatment
AT rozetfrancois radium223dichlorideforprostatecancertreatment
AT kassabchahmidiana radium223dichlorideforprostatecancertreatment
AT rebillardxavier radium223dichlorideforprostatecancertreatment
AT houedenadine radium223dichlorideforprostatecancertreatment

Ejemplares similares